|
|
|
13.10.25 - 14:36
|
Singapore′s Nanyang Biologics to list on Nasdaq amid Trump′s pharma tariffs. (SCMP)
|
|
|
Nanyang Biologics, a Singapore-based artificial intelligence drug discovery start-up, plans to list on the Nasdaq stock exchange in the first quarter of 2026 via a merger with a US-listed special-purpose acquisition company (SPAC), as US President Donald Trump vowed to impose hefty tariffs on pharmaceutical imports.
“The US administration wants intellectual property owners to manufacture in the US, including drugs,” founder Roland Ong said on Monday.
Nanyang Biologic's latest initiative reflects......
|
|
|
|
|
|
|
06.10.25 - 06:06
|
Australian AI healthcare start-up eyes Hong Kong, Singapore markets (SCMP)
|
|
|
Australian healthcare technology start-up Heidi has secured US$65 million in a new funding round, as it aims to expand its workforce and establish offices in Hong Kong and Singapore to capitalise on the growing demand for medical artificial intelligence technology in the region.
The company is valued at US$465 million following its series B round announced on Monday, led by Point72 Private Investments, a global alternative asset manager.
The six-year-old start-up planned to build a team of about......
|
|
|
02.10.25 - 13:03
|
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia (GlobeNewswire EN)
|
|
|
SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce the publication of a preclinical study, in a research article entitled “Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “off-the-shelf” Immunotherapy Approach”. The study results from this collaborative research with The University of Texas, MD Anderson Cancer Center (MDACC), are suggesting the promising potential of CytoMed's allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). This collaboration with MDACC is under a previously announced research agreement in May 2023. The research article is now publicly and freely online at Donor-Der...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.09.25 - 22:03
|
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors (GlobeNewswire EN)
|
|
|
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013....
|
|
|
|
|
|
|
|
|
|
|
|
|
28.08.25 - 15:03
|
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition (GlobeNewswire EN)
|
|
|
SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce it has successfully expanded clinical-scale natural killer (“NK”) cells from cord blood units that have been cryopreserved for more than a decade. This sets the impetus for establishing a new business platform to generate additional revenue streams and future growth....
|
|
|
|
|
21.08.25 - 09:18
|
Qlife together with Birmingham Women′s and Children′s NHS Foundation Trust achieve positive results for its rare disease self-test PHE product (Cision)
|
|
|
Gothenburg, Sweden - Qlife Holding AB (“Qlife” or the “Company”) announces that it has finalized its clinical study for children and young people under 18 years of age. The study was focused on the self-test at-home aspect and the comparison of data to standard of care methodology DBS-cards (Dried Blood Spots). The study and the enrollment were completed under the leadership of Professor Anita MacDonald, Professor in Dietetics at Birmingham Women's and Children's NHS Foundation Trust.
Summary of results:
· High concordance between Egoo PHE Test results and the Dry Blood Spot (DBS)...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
